BACKGROUND: The clinical results of definitive-dose preoperative chemoradiotherapy (CRT) of 50 Gy/25 fractions/5 weeks for unresectable esophageal cancer were analyzed. METHODS: Inclusion criteria were unresectable esophageal squamous cell carcinoma with T4b or mediastinal lymph nodes invading to the trachea or aorta. Radiation therapy of 50 Gy/25 fractions/5 weeks was combined concurrently with two courses of FP therapy (CDDP 70 mg/m(2) + 5-FU 700 mg/m(2)/d × 5 days: day 1-5, day 29-33). Tumor response was evaluated 4 weeks after completion of RT. Subtotal esophagectomy was planned 6-8 weeks after RT. RESULTS: Thirty patients (26 male and 4 female) aged from 50-78 years (median 66) were enrolled between 2008 and 2011. The clinical stages according to the 7th edition of UICC were stages II/III/IV, 1/23/6; T1/2/3/4, 1/1/4/24; and N0/1/2/3, 3/25/1/1. All 30 patients completed RT of 50 Gy/25 fractions. Initial tumor responses were 21 patients with resectable disease, 7 with unresectable disease, and 2 with progressive disease. Subtotal esophagectomy was performed in 18 (60%) of the 30 patients. Pathological complete response was obtained in five (28%) patients. There were two patients with hospitalization death after surgery (11%). Six of the 7 patients who still had unresectable disease were treated with 1-3 courses of docetaxel, CDDP and 5-FU. Three patients treated without surgery showed long-term survival. The 3-year loco-regional control rate and the 3-year overall survival rate for the 30 patients were 70 and 49%, respectively. CONCLUSIONS: Definitive-dose preoperative CRT was feasible, and is a promising treatment strategy for unresectable esophageal cancer.
BACKGROUND: The clinical results of definitive-dose preoperative chemoradiotherapy (CRT) of 50 Gy/25 fractions/5 weeks for unresectable esophageal cancer were analyzed. METHODS: Inclusion criteria were unresectable esophageal squamous cell carcinoma with T4b or mediastinal lymph nodes invading to the trachea or aorta. Radiation therapy of 50 Gy/25 fractions/5 weeks was combined concurrently with two courses of FP therapy (CDDP 70 mg/m(2) + 5-FU 700 mg/m(2)/d × 5 days: day 1-5, day 29-33). Tumor response was evaluated 4 weeks after completion of RT. Subtotal esophagectomy was planned 6-8 weeks after RT. RESULTS: Thirty patients (26 male and 4 female) aged from 50-78 years (median 66) were enrolled between 2008 and 2011. The clinical stages according to the 7th edition of UICC were stages II/III/IV, 1/23/6; T1/2/3/4, 1/1/4/24; and N0/1/2/3, 3/25/1/1. All 30 patients completed RT of 50 Gy/25 fractions. Initial tumor responses were 21 patients with resectable disease, 7 with unresectable disease, and 2 with progressive disease. Subtotal esophagectomy was performed in 18 (60%) of the 30 patients. Pathological complete response was obtained in five (28%) patients. There were two patients with hospitalization death after surgery (11%). Six of the 7 patients who still had unresectable disease were treated with 1-3 courses of docetaxel, CDDP and 5-FU. Three patients treated without surgery showed long-term survival. The 3-year loco-regional control rate and the 3-year overall survival rate for the 30 patients were 70 and 49%, respectively. CONCLUSIONS: Definitive-dose preoperative CRT was feasible, and is a promising treatment strategy for unresectable esophageal cancer.
Authors: E F W Courrech Staal; B M P Aleman; H Boot; M-L F van Velthuysen; H van Tinteren; J W van Sandick Journal: Br J Surg Date: 2010-10 Impact factor: 6.939
Authors: Giovanni de Manzoni; Corrado Pedrazzani; Felice Pasini; Marco Bernini; Anna Maria Minicozzi; Simone Giacopuzzi; Antonio Grandinetti; Claudio Cordiano Journal: J Surg Oncol Date: 2007-03-01 Impact factor: 3.454
Authors: J F Bosset; M Gignoux; J P Triboulet; E Tiret; G Mantion; D Elias; P Lozach; J C Ollier; J J Pavy; M Mercier; T Sahmoud Journal: N Engl J Med Date: 1997-07-17 Impact factor: 91.245
Authors: A Ohtsu; N Boku; K Muro; K Chin; M Muto; S Yoshida; M Satake; S Ishikura; T Ogino; Y Miyata; S Seki; K Kaneko; A Nakamura Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: M Yano; T Tsujinaka; H Shiozaki; M Inoue; Y Doki; M Yamamoto; E Tanaka; T Inoue; M Monden Journal: J Surg Oncol Date: 1999-01 Impact factor: 3.454
Authors: F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà Journal: Gut Date: 2004-07 Impact factor: 23.059
Authors: Doreen Dähn; Joachim Martell; Hilke Vorwerk; Clemens F Hess; Heinz Becker; Klaus Jung; Reinhard Hilgers; Hendrik Andreas Wolff; Robert Michael Hermann; Hans Christiansen Journal: Int J Radiat Oncol Biol Phys Date: 2009-08-11 Impact factor: 7.038
Authors: I L Defize; S van der Horst; M Bülbul; N Haj Mohammad; S Mook; G J Meijer; L A A Brosens; J P Ruurda; R van Hillegersberg Journal: Ann Surg Oncol Date: 2020-12-19 Impact factor: 5.344